Daratumumab as a Frontline Immunosuppression for Pure Red Cell Aplasia after Major ABO-mismatched Allogeneic Hematopoietic Stem Cell Transplantation

被引：3
|
作者：
Asawapanumas, Thiti [1 ,2 ,3 ]
Chanswangphuwana, Chantiya [1 ,2 ,3 ]
Watanaboonyongcharoen, Phandee [4 ,5 ]
Rojnuckarin, Ponlapat [1 ,2 ,3 ]
Bunworasate, Udomsak [1 ,2 ,3 ]
机构：
[1] Chulalongkorn Univ, Fac Med, Div Hematol, Dept Med, Rama IV Rd, Bangkok 10330, Thailand
[2] King Chulalongkorn Mem Hosp, Rama IV Rd, Bangkok 10330, Thailand
[3] Chulalongkorn Univ, Res Unit Translat Hematol, Bangkok, Thailand
[4] Chulalongkorn Univ, Fac Med, Dept Lab Med, Bangkok, Thailand
[5] King Chulalongkorn Mem Hosp, Transfus Med Unit, Bangkok, Thailand
来源：
LEUKEMIA RESEARCH REPORTS | 2022年 / 17卷
关键词：
Daratumumab; Pure red cell aplasia; Major ABO-mismatched;
D O I：
10.1016/j.lrr.2022.100314
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Case report: Successful treatment with daratumumab for pure red cell aplasia in a patient with mixed lymphoid chimerism after ABO-mismatched stem cell transplant for sickle cell disease
    Dovern, E.
    Biemond, B. J.
    Nur, E.
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [32] RED BLOOD CELL CHIMERISM EVALUATION IN MAJOR ABO-MISMATCHED ALLOGENEIC
    Zielinska, P.
    Dzierzak-Mietla, M.
    Markiewicz, M.
    Koclega, A.
    Bialas, K.
    Jagoda, K.
    Kyrcz-Krzemien, S.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S557 - S557
  • [33] Treatment for pure red cell aplasia after major ABO-incompatible allogeneic stem cell transplantation: a multicentre study
    Longval, Thomas
    Galimard, Jacques-Emmanuel
    Lepretre, Anne-Claire
    Suarez, Felipe
    Amiranoff, Denise
    Cazaux, Marine
    Kaphan, Eleonore
    Michonneau, David
    Dhedin, Nathalie
    Coman, Tereza
    Quoc, Stephanie Nguyen
    de Latour, Regis Peffault
    Resche-Rigon, Matthieu
    de Fontbrune, Flore Sicre
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (04) : 814 - 826
  • [34] Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question
    Javier Marco-Ayala
    Inés Gómez-Seguí
    Guillermo Sanz
    Pilar Solves
    Bone Marrow Transplantation, 2021, 56 : 769 - 778
  • [35] Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question
    Marco-Ayala, Javier
    Gomez-Segui, Ines
    Sanz, Guillermo
    Solves, Pilar
    BONE MARROW TRANSPLANTATION, 2021, 56 (04) : 769 - 778
  • [36] Prevalence of Pure Red Cell Aplasia Following Major ABO-Incompatible Hematopoietic Stem Cell Transplantation
    Zhu, Panpan
    Wu, Yibo
    Cui, Dawei
    Shi, Jimin
    Yu, Jian
    Zhao, Yanmin
    Lai, Xiaoyu
    Liu, Lizhen
    Xie, Jue
    Huang, He
    Luo, Yi
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [37] Successful treatment of refractory pure red cell aplasia with eltrombopag after ABO-incompatible allogeneic hematopoietic stem cell transplantation
    Gao, Yang
    Gao, Fei
    Shi, Jimin
    Fu, Huarui
    Huang, He
    Zhao, Yanmin
    JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2021, 22 (08): : 695 - 700
  • [38] Successful Treatment of Pure Red Cell Aplasia with Rituximab in Patients after ABO-Compatible Allogeneic Hematopoietic Stem Cell Transplantation
    Jung, Sung-Hoon
    Ahn, Jae-Sook
    Yang, Deok-Hwan
    Park, Hyung Chul
    Bae, Soo-Young
    Kim, Yeo-Kyeoung
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    CASE REPORTS IN ONCOLOGY, 2012, 5 (01): : 110 - 113
  • [39] Clinical features and risk factors of pure red cell aplasia following major ABO-incompatible allogeneic hematopoietic stem cell transplantation
    Zhu, Kang-Er
    Li, Jun-Ping
    Zhang, Tao
    Zhong, Juan
    Chen, Jie
    HEMATOLOGY, 2007, 12 (02) : 117 - 121
  • [40] Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab
    Salas, Maria Queralt
    Alahmari, Ali
    Lipton, Jeffrey Howard
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (02) : 145 - 147
12345